Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer
March 15, 2025 11:25 ET | Source: ZENTALIS PHARMACEUTICALS Azenosertib median duration…
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2025 17:42 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Feb.…
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Results from DENALI Part 1b show an Objective Response Rate (ORR) of…
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024 19:04 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Nov.…